title: Microparticulate β-glucan vaccine conjugates phagocytized by dendritic cells activate both naïve CD4 and CD8 T cells in vitro.
abstract: Microparticulate β-glucan (MG) conjugated to vaccine antigen has been shown to serve as an effective adjuvant in vivo. To further study antigen presentation by MG:vaccine conjugates, bone marrow-derived dendritic cells (BMDC) were treated with MG conjugated to ovalbumin (OVA), then interacted with splenocytes from DO11.10 transgenic mice expressing an OVA peptide-specific T cell receptor. BMDC treated with MG:OVA induced significantly higher numbers of activated (CD25+CD69+) OVA-specific CD4+ T cells than BMDC treated with OVA alone. BMDC treated with MG:OVA upregulated CD86 and CD40 expression as well as MG alone, indicating that conjugation of OVA does not alter the immunostimulatory capacity of MG. Activation of CD8+ OVA-specific OT-1 cells showed that MG:OVA is also capable of enhancing cross-presentation by BMDC to CD8+ cytotoxic T cells. These results show that MG acts as an adjuvant to enhance antigen presentation by dendritic cells to naïve, antigen-specific CD4 and CD8 T cells.
authors.affiliation: Department of Microbiology and Immunology, University of Nevada School of Medicine, Reno, NV, United States.
authors.forename: Vanessa K
authors.initials: VK
authors.lastname: Berner
authors.affiliation: Department of Microbiology and Immunology, University of Nevada School of Medicine, Reno, NV, United States.
authors.forename: Sally A
authors.initials: SA
authors.lastname: duPre
authors.affiliation: Department of Physiology and Cell Biology, University of Nevada School of Medicine, Reno, NV, United States.
authors.forename: Doug
authors.initials: D
authors.lastname: Redelman
authors.affiliation: Department of Microbiology and Immunology, University of Nevada School of Medicine, Reno, NV, United States. Electronic address: khunter@medicine.nevada.edu.
authors.forename: Kenneth W
authors.initials: KW
authors.lastname: Hunter
mesh_terms: D000276:Adjuvants, Immunologic / Q000494:pharmacology; D000818:Animals; D017951:Antigen Presentation / Q000276:immunology; D051940:B7-2 Antigen / Q000096:biosynthesis; D001854:Bone Marrow Cells / Q000276:immunology; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology*; D019013:CD40 Antigens / Q000096:biosynthesis; D002478:Cells, Cultured; D003713:Dendritic Cells / Q000276:immunology*; D005260:Female; D008213:Lymphocyte Activation / Q000187:drug effects*; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D010047:Ovalbumin / Q000276:immunology; D061251:Primary Cell Culture; D012441:Saccharomyces cerevisiae / Q000378:metabolism; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D047071:beta-Glucans / Q000276:immunology* / Q000494:pharmacology
chemical_list: D000276:Adjuvants, Immunologic; D051940:B7-2 Antigen; D019013:CD40 Antigens; C497965:Cd86 protein, mouse; D047071:beta-Glucans; D010047:Ovalbumin
keywords: CD4 T cells; CD8 T cells; Dendritic cells; Vaccine adjuvant; β-Glucan